CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827573] of Tables ................................................................................................................................... 5
1.Protocol Summary ..................................................................................................................... 6
1.1. Synopsis ........................................................................................................................... 6
1.2. Schema ............................................................................................................................ 9
1.3. Schedule of Activ ities (SoA) ......................................................................................... 10
2.Introduction.............................................................................................................................. 13
2.1. Study  Rationale ................................................................ ............................................. 13
2.2. Background ................................................................................................................... 14
2.3. Benefit/Risk Assessment ............................................................................................... 14
3. Objectives and Endpoints ........................................................................................................ 16
4.Study  Design ............................................................................................................................ 17
4.1. Overall Design ............................................................................................................... 17
4.2. Scientific Rationale for Study  Design ........................................................................... 17
4.3. Justification for Dose..................................................................................................... 17
4.4. End of Study  Definition ................................................................ ................................ 18
5.Study Population ...................................................................................................................... 19
5.1. Inclusion Criteria ................................................................ ........................................... 19
5.2. Exclusion Criteria .......................................................................................................... 20
5.3. Lifesty le Considerations ................................................................................................ 22
5.4. Screen Failures .............................................................................................................. 22
6.Study  Intervention .................................................................................................................... 23
6.1. Study  Intervention(s) Administered ................................................................ .............. 23
6.2. Preparation/Handling/Storage/Accountability .............................................................. 23
6.3. Measures to Minimize Bias: Randomization and Blinding ........................................... 24
6.4. Study  Intervention Compliance ................................................................ ..................... 24
6.5. Concomitant Therap y.................................................................................................... 24
6.5.1. Prohibited I nterventions and Washout Before the 
Study ................................................................
............................................... 24
6.5.2. Permitted I nterventions .................................................................................. 25
6.5.3. Rescue Medicine ............................................................................................ 25
6.5.4. Prohibited I nterventions During the Study ..................................................... 25
6.6. Dose Modification......................................................................................................... 25
6.7. Intervention after the End of the Study ......................................................................... 25
7.Discontinuation of Study I ntervention and Participant 
Discontinuation/Withdrawal .................................................................................................... 26
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827574] -T-01 -01 v3.07.1. Discontinuation of Study Intervention .......................................................................... 26
7.2. Participant Discontinuation/Withdrawal from the Study .............................................. [ADDRESS_827575] ................................................................ .33
8.4. Treatment of Overdose ................................
.................................................................. 33
8.5. Pharmacokinetics ........................................................................................................... 34
8.6. Pharmacod ynamics ........................................................................................................ 34
8.7. Genetics ......................................................................................................................... 34
8.8. Biomarkers and Other Assessments .............................................................................. 34
8.9. Health Economics OR Medical Resource Utilization and Health 
Economics ..................................................................................................................... 34
9. Statistical Considerations ......................................................................................................... 35
9.1. Statistical Hy potheses .................................................................................................... 35
9.2. Sample Size Determination ........................................................................................... 35
9.3. Populations for Analy ses............................................................................................... 35
9.4. Statistical Analy ses................................................................ ........................................ 35
9.4.1. General C onsiderations .................................................................................. 36
[IP_ADDRESS]. Analy sis Endpoints ....................................................................... 36
[IP_ADDRESS]. Primary  Anal yses................................................................ ......... 37
[IP_ADDRESS]. Secondary  Anal yses..................................................................... 37
9.4.2. Safety Anal yses................................................................ .............................. 37
[IP_ADDRESS]. Adverse Events ............................................................................. 37
[IP_ADDRESS]. Clinical L aboratory  Assessments ................................................. 38
[IP_ADDRESS]. Vital Signs .................................................................................... 38
9.4.3. PK Analy ses................................................................................................... 38
9.4.4. Other Anal yses................................................................ ............................... 38
[IP_ADDRESS]. Subgroup Analy ses....................................................................... 39
9.5. Interim Anal yses............................................................................................................ 39
10.Supporting Documentation and Operational Considerations .................................................. 40
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827576] -T-01 -01 v3.010.1. Appendix 1: Regulatory , Ethical, and Study  Oversight 
Considerations ............................................................................................................... 41
10.1.1. Regulatory  and Ethical Considerations .......................................................... 41
10.1.2. Financ ial Disclosure ................................
....................................................... 41
10.1.3. Informed Consent Process ................................................................ .............. 42
10.1.4. Data Protection ............................................................................................... 42
10.1.5. Dissemination of Clinical Study  Data ............................................................ 42
10.1.6. Data Qualit y Assurance ................................................................ .................. 43
10.1.7. Source Documents .......................................................................................... 43
10.1.8. Study  and Site Start and Closure ................................................................ ....44
10.1.9. Publication Policy ........................................................................................... 44
10.1.10. Compliance with Protocol .............................................................................. 45
10.2. Appendix 2: Clinical L aboratory  Tests ................................................................ ......... 46
10.3. Appendix 3: Adverse Events: Definitions an d Procedures for 
Recording, Evaluating, Follow -up, and Reporting ........................................................ 47
10.3.1. Definition of AE ............................................................................................. 47
10.3.2. Definition of SAE ........................................................................................... 49
10.3.3. Recording and Follow -up of AE and/or SAE ................................................ 50
10.3.4. Reporting of SAEs .......................................................................................... 52
10.4. Appendix 4: Abbreviations ........................................................................................... 53
10.5. Appendix 5: Standard Discontinuation Criteria ............................................................ 55
10.6. Appendix 6: Study Tabular Summary ........................................................................... 56
10.7. Appendix 7: Contraceptive Guidance and Collection of 
Pregnancy  Information .................................................................................................. 57
11.References ................................................................................................................................ 59
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827577] of Tables
Table 1-1 Schedule of Activities ........................................................................................... 10
Table 6-1 Study  Interventions ............................................................................................... 23
Table10-1 Protocol -required Safet y Laboratory  Assessments ............................................... 46
Table 10-2 Highl y Effective and Acceptable Contraceptive Methods.................................... 57
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827578] -T-01 -01 v3.01. Protocol Summary
1.1. Synopsis
Protocol Title: A Phase IV, Multi -center, Open- label, Single -arm, 24- hour Ambulatory  Blood 
Pressure Monitoring (ABPM) Study  of 16 Weeks Treatment with Androderm® in Hy pogonadal 
Men
Protocol Number: 3146 -402-016
Brief Title: Androderm®(testosterone transdermal sy stem)
Study Rationale :
Prior clinical studies of Androderm collected and evaluated p re-and post -treatment s ystolic and 
diastolic blood pressure ( BP)by [CONTACT_621751]. No significant trends in cuff BP values were 
noted in patients treated with Androderm.
The Food and Drug Administr ation ( FDA )has issued a post approval requirement because it is 
not fully  known whether any  changes in BP, when assessed using [ADDRESS_827579] of 
once dail y Androderm on BP parameters as measured b y 24-hour ABPM in hy pogonadal men 
after 16 weeks of treatment.
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827580] -T-01 -01 v3.0Objectives and Endpoint s:
Objectives Endpoints
Prim ary
To determine whether Androderm has a 
meaningful effect on 24-hour average systolic 
blood pressure (SBP) as measured by [CONTACT_621752] Change from baseline in 24 -hour average SBP 
obtained at Week 16
Secondary
To determine whether Androderm has a 
meaningful effect on 24-hour blood pressure 
(BP) parameters as measured by [CONTACT_621753]Change from baseline in 24 -hour average diastolic 
blood pressure ( DBP ), mean arterial pre ssure ( MAP ), 
pulse pressure and heart rate obtained at Week 16
Exploratory
To determine whether Androderm has a 
meaningful effect on BP parameters as 
measured by [CONTACT_621754]Change from baseline in daytime average SBP, DBP, 
MAP, pulse pressure and heart rate obtained at 
Week 16
Change from baseline in night -time average SBP, 
DBP, MAP, pulse pressure and heart rate obtained at 
Week 16
Change from baseline over time (hourly average) by 
[CONTACT_621755]: SBP, DBP, 
MAP, pulse pressure and heart rate
Status (yes/no) of participants with new 
anti-hypertensive medications
Status (yes/no) of participants with dose increases in 
anti-hypertensive medications
Outlier responder for participants meeting SBP 
≥160mmHg for 24 -hour average
Outlier responder for participants meeting SBP 
change from baseline ≥20 mm Hg for 24 -hour 
average 
Outlier responder for participants meeting DBP 
≥100mmHg for 24 -hour average 
Outlier responder f or participants meeting DBP 
change from baseline ≥15 mm Hg for 24 -hour 
average 
Status (yes/no) of participants with normalized 
testosterone concentrations at Week 16
Safety
To demonstrate the safety of once daily 
Androderm for 16 w eeks in hypogonadal menSafety Param eters
Adverse events (A Es), clinical laboratory values, vital 
signs , and physical examination
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827581] -T-01 -01 v3.0Overall Study Design :  
This is a multi -center, open -label, single -arm study in h ypogonadal men to evaluate the effect of 
once dail y Androderm on BP parameters as measured b y 24-hour ABPM.
Number of Participant s:  
Approximately  300 participants will be screened ,to achieve 150 enrolled who receive 
≥ 1administration of study intervention, and [ADDRESS_827582] 24 -hour ABPM assessment.
Intervention Groups and Study Duration :  
The study  will consist of a screening period of approximately  3 weeks (21 day s), followed by  [CONTACT_621756] 16 weeks (minimum of 113 + 7 days), for a total study  duration of 
approximately  19 weeks (133 day s). All participants who meet the criteria for participation in the 
study  will be administered Androderm at the starting dose of 4 mg/day . On Visit 2, study  
participants will have morning serum concentration s of testosterone measured. If participants 
have a serum concentration below 400 ng/dL, the dose of Androderm will be increased to 
6mg/day  (one 4 mg/day  system and one 2 mg/day sy stem). If the serum concentration is above 
930 ng/dL, the dose of Androderm will be decreased to 2 mg/day . All others will rema in on 
4mg/day .
Data Monitoring Committee: No
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827583] -T-01-01 v3.01.2. Schema

CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827584] 
throughout a man’s life. Testosterone exerts its development of secondary  sex characteristics in 
men during pubert y, in w hich men begin to observe growth and maturation of the prostate, penis, 
scrotum, etc. ( Ullah 2014 ). 
Hypogonadism is a condition that results from insufficient ph ysiological concentrations of serum 
testosterone produced b y the testes and/or an abnormal number of spermatozoa present. 
Hypogonadism is split into primary  and secondary hy pogonadism. Primary  hypogonadism 
occurs when there are abnormalities in the testes, whereas secondary h ypogonadism is seen when 
there are defects in the hy pothalamus or the pi[INVESTIGATOR_2117] . Signs and s ymptoms associated with 
hypogonadism include delay ed sexual development, loss of body  hair, reduced libido, erectile 
dysfunction, fatigue, mood depression, and osteoporosis ( Bhasi n 2018 ).
Testosterone replacement therap y has been used to maintain secondary sex characteristics and to 
halt sy mptoms of testosterone deficiency  (Bhasin 2018 ). Androderm®(testosterone transdermal 
system) is an androgen indicated for replacement therap y in adult men with conditions associated 
with a deficiency  or absence of endogenous testosterone. Through its self -contained transdermal 
system, Androderm provides a continuous daily  dose of testosterone ,delivering ph ysiologic 
concentrations of testoster one,resulting in circulating testosterone levels that are approximately  
equal to the normal concentration range seen in healthy adult men (300 to 1030 ng/dL). 
Androderm has been available since 29 Sep tember 1995 and is recognized as a replacement 
therap y in males for the indications of primary  hypogonadism (congenital or acquired) and 
hypogonadotropic hy pogonadism (congenital or acquired) ( Allergan 2018 ).
2.1. Study Rationale
Prior clinical studies of Androderm collected and evalu ated pre -and post -treatment s ystolic and 
diastolic BP by  [CONTACT_621751]. No significant trends in cuff BP values were noted in 
patients treated with Androderm.
The FDA has issued a postapproval requirement because it is not fully  known whether any  
chan ges in BP, when assessed using [ADDRESS_827585] of Androderm on BP. Tw enty-four-hour 
ABPM provides a much larger number of readings throughout the day and night, providing more 
reproducible mean 24 -hour, day time, and night -time values. It more accurately  identifies 
white- coat h ypertension, where clinic BP measurements are hi gh but ABPM readings are 
normal, and masked h ypertension, where clinic BP measurements are low but ABPM readings 
are high ( Parati 2014 ).
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827586] ( Dupont 1987 , Mutti 1991 , Mancia 1995 ). 
Dupont etal demonstrated that p lacebo significantly  decreased in -clinic s ystolic and diastolic BP 
when measured b y cuff measurements after 4 weeks (p < 0.001) but did not significantly 
decrease s ystolic and diastolic BP when measured by  [CONTACT_44117]. Similarly , Mutti et al demonstrated 
that,following 4 weeks of placebo, in -clinic sy stolic and diastolic BP was significantl y reduced 
(-9.6±2.6 and -3.1 ± 1.7 mmHg, p < 0.01, respectively ), while 24 -hour ABPM did not show 
any significant change. Finally , Mancia et al again demonstrated that admin istration of placebo 
significantl y decreased systolic and diastolic BP measured in the clinic ( -5.3 ± 1.1 and -4.4 
±0.6mmHg, p <0.01, respectively), while no significant reductions were noted with [ADDRESS_827587] it has on BP para meters 
is not fully  understood.
2.3. Benefit/Risk Assessment
Patients with either primary  hypogonadism (congenital or acquired) or h ypogonadotropic 
hypogonadism (congenital or acquired), characterized by  [CONTACT_621757] 
<300ng/dL, may  experience symptoms that include, but are not limited to, erectile d ysfunction, 
osteoporosis, fatigue, decreased libido, hot flashes, etc.
In several clinical trials of males between 15 and 76 years old, partic ipants with male 
hypogonadism were treated with 2 mg/day to 5 mg/day  of Androderm for up to 28 day s. 
Androderm produced average morning serum testosterone concentrations within the normal 
reference range in 92 %to 97% of participants ( Allergan 2018 ).
The most common adverse reactions reported in clinical trials were application site reactions in 
28% to 48% of participants. Other less common adverse reactions are prostate abnormalities, 
headache, and depression (reported in 5%, 4%, and 3% of participant s in clinical studies). 
Adverse reactions reported by  < 3% of participants included: chills, diarrhea, rash, fatigue, 
gastrointestinal bleeding, gastroesophageal reflux disease, hemarthrosis, hematuria, polyuria, 
prostatitis, body  pain, pelvic pain, hy pertension, peripheral vascular disease, increased appetite, 
accelerated growth, anxiety , confusion, decreased libido, impotence, paresthesia, thinking 
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827588], the benefit -risk of A ndroderm remains 
positive when used for approved indications.
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827589] -T-01 -01 v3.03. Objectives and Endpoints
Objectives Endpoints
Prim ary
To determine whether Androderm has a 
meaningful effect on 24-hour average SBP as 
measured by [CONTACT_621754] Change from baseline in 24 -hour average SBP 
obtained at Week 16
Secondary
To determine whether Androderm has a 
meaningful effect on 24-hour BP parameters as 
measured by [CONTACT_621758]Change from baseline in 24 -hour average DBP, MAP, 
pulse pressure and heart rate obtained at Week 16
Exploratory
To determine whether Androderm has a 
meaningful effect on BP parameters as 
measured by [CONTACT_621754]Change from baseline in daytime average SBP, DBP, 
MAP, pulse pressure and heart rate obtained at 
Week 16
Change from baseline in night -time average SBP, 
DBP, MAP, pulse pressure and heart rate obtained at 
Week 16
Change from baseline over time (hourly average) by 
[CONTACT_621755]: SBP, DBP, 
MAP, pulse pressure and heart rate
Status (yes/no) of participants with new 
anti-hypertensive medications
Status (yes/no) of participants with dose increases in 
anti-hypertensive medications
Outlier responder for participants meeting SBP 
≥160mmHg for 24 -hour average
Outlier responder for participants meeting SBP 
change from baseline ≥20 mm Hg for 24 -hour 
average 
Outlier responder for participants meeting DBP 
≥100mmHg for 24 -hour average 
Outlier responder for participants meeting DBP 
change from baseline ≥15 mm Hg for 24 -hour 
average 
Status (yes/no) of participants with normalized 
testosterone concentrations at Week 16
Safety
To demonstrate the safety of once daily 
Androderm for 16 w eeks in hypogonadal menSafety Param eters
Adverse events (A Es), clinical laboratory values, vital 
signs , and physical examination
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827590] of a screening period of approximately  3 weeks (21 day s), followed by  [CONTACT_621756] 16 weeks (minimum of 113 + 7 days), for a total study  duration of 
approximately  19 weeks (133 day s). All participants who meet the criteria for participation in the 
study  will be administered Androderm at the starting dose of 4 mg/day . On Visit 2, study  
participants will have morning serum concent rations of testosterone measured. If participants 
have a serum concentration below 400 ng/dL, the dose of Androderm will be increased to 
6mg/day  (one 4 mg/day  system and one 2 mg/day sy stem). If the serum concentration is above 
930 ng/dL, the dose of Andr oderm will be decreased to 2 mg/d ay. All others will remain on 
4mg/day.
Approximately  [ADDRESS_827591] with ABPM ( Dupont 1987 , Mutti 1991 , 
Mancia 1995 ). ABPM more accuratel y identifies white -coat h ypertension, where clinic BP 
measurements are high but ABPM readings are normal , and masked hy pertension, where clinic 
BP measurements are low but ABPM readings are high ( Parati 2014 ).
4.3. Justification for Dose
Androderm is approved by  [CONTACT_621759] y of endogenous testosterone in 
males with primary  hypog onadism (congenital or acquired) and h ypogonadotropic 
hypogonadism (congenital or acquired). The recommended starting dose for Androderm is one 
4mg/day  system, applied nightly ,every  24 hours. 2 mg/day  and 4 mg/day Androderm 
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827592] completed the study  if he has not been terminated early  and 
has completed all phases of the study  including Visit 6 (Day 113 [+ 7 day s]).
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827593] y:
1. Age
1.[ADDRESS_827594] be 18 to 80years of age inclusive, at the time of signing the informed 
consent
2. Type of Participant and Diseas eCharacter istics
2.01Two serum testosterone levels < 300 ng/dL in the morning ,between 0700and 11 00local 
participant’s time ,on 2separate day s,at least [ADDRESS_827595] 6 months
3. Weight and Body Mass Index
3.01 BMI < 35 kg/m2
4. Sex
4.[ADDRESS_827596] dose of study  
intervention and refrain from donating sperm during this period.
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827597] -T-01 -01 v3.06. Informed Consent
6.01 Capable of giving signed informed consent as described in Appendix 1, which includes 
compliance with the requirements and restrictions listed in the I CF and in this protocol
6.02 Signed informed consent from the participant has b een obtained prior to any 
study -related procedures.
6.03Signed documentation has been obtained in accordance with the relevant country  and 
local privacy requirements, where applicable (eg, Written Authorization for Use and 
Release of He alth and Research Stud y Information)
7. Other
7.01 Able, as assessed b y the investigator, and willing to follow study instructions and likely  
to complete all required study  visits
5.2. Exclusion Criteria
Participants are excluded from the study if an y of the following criteria apply :
1. Medical Conditions
1.01Uncontrolled s ystemic disease or clinically significant disease, in particular, liver, kidney  
or heart disease, including hypertension, congestive heart failure, coronary heart disease, 
chronic atrial fibrillation, sleep apnea or ps ychiatric illness, that in the investigator’s 
opi[INVESTIGATOR_1649], would put the participant at an unacceptable risk with exposure to Androderm
1.02 History  of prostate (current or in the past) or breast cancer
1.03 Had a recent (within 2 y ears) history  of stroke, transient ischemic attack, acute coronary  
event, venous thrombotic, or thromboembolic event
1.04 History  of alcohol or other substance abuse within the previous 2years
1.05 Known allergy  or sensitivity  to the study  intervention or its components or other 
testosterone replacement medications
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827598] -T-01 -01 v3.02. Prior/Concomitant Therapy
2.[ADDRESS_827599] be stable (for at least 4 weeks) with 
no intention of changing during screening and for the duration of the stud y:
Medications for diabetes, hypertension, hy perlipi[INVESTIGATOR_035] , or anticoagulation
Glucocorticoids > 7.5 mg prednisone equivalent per day (eg , hydrocortisone 
30mg, meth ylprednisolone 6 mg , or dexamethasone 1.2 mg)
2.02 Use of an y over -the-counter or herbal preparations containing testosterone is prohibited 
within 7 day s or 5 half -lives (whichever is longer) prior to screening and for the duration 
of the study
3. Prior/Concurrent Clinical Study Experience
3.01 Current enrollment in an investigational drug or device stud y or participation in such a 
study  within 30 days of entry  into this study
4. Diagnostic Assessments
4.01 Mean triplicate sitting BP (by [CONTACT_32606]) > 140/90 mm Hg during all screening visits
4.02 HbA1c > 8.5%
4.03 Abnormal prostate digital rectal examination (palpable nodules) within 6 months of 
screening
4.04 PSA > 3.0 ng/mL
4.05 Hematocrit > ULN
4.06 Prolactin > ULN
4.[ADDRESS_827600] sy mptoms as indicated by  [CONTACT_1629] I-PSS > 19 at screening
4.08 Abnormal and clinicall y significant results according to the investigator or designee, on 
physical examination, medical history , hematology , clinical chemistry , or urinaly sis
5. Other
5.01 Participant who works night shifts or who will need to perform strenuous manual labor 
while wearing the ABPM monitor
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827601] -T-01 -01 v3.05.02 Participant has a condition or is in a situation that, in the investigator’s opi[INVESTIGATOR_1649], may put 
the participant at significant risk, may confound the study results, or may interfere 
significantl y with the participant’s participation in the study
5.[ADDRESS_827602] and administration of this study as an 
investigator, subinvestigator, study  coordinator, or other study  staff member; employ ee 
of the sponsor; first degree famil y member, significant other, or relative residin g with one 
of the above persons involved directl y or indirectly in the stud y; or enrolled in the study  
by[CONTACT_621760]
5.3. Lifestyle Considerations
No lifesty le considerations or restrictions are required.
5.4. Screen Failures
Screen failures are defined as participant s who consent to participate in the clinical study but are 
not subsequent ly entered in the study .
A minimal set of screen failure information is required to ensure transparent reporting of screen 
failure participants to meet the CONSORT publi shing requirements and to respond to queries 
from r egulatory  authorities. Minimal information includes indicating screen failure as reason for 
ending the stud y, demography , screen failure details, eligibility  criteria, and any  SAE .
Individuals who do not m eet the criteria for participation in this study (screen failure s) may not
be re screened.
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827603] -T-01 -01 v3.06. Study Intervention
Study  intervention is defined as an y investigational intervention(s), marketed product(s), 
placebo ,or medical device (s)intended to be administered to a study  participant according to the 
study  protocol.
6.1. Study Intervention(s) Administered
Table 6-1 Study Interventions
Study Intervention Name [CONTACT_621769]® (testosterone transdermal syste m)
Dose Formulation 2 mg/day and 4 mg/day transdermal system
Route of Adm inistration Transdermal
Dosing InstructionsAll participants will receive a starting dose of Androderm 4mg/day 
applied nightly at approximately 2200 . At Visit 2, a fasting morning 
testosterone concentration will be measured. A testosterone concentration 
< 400 ng/dL will require an increase in dose to 6 mg/day (one 4 mg/day
system and one 2 mg/day system) applied nightly. A testosterone 
concentrati on > 930 ng/dL will require a decrease in dose to 2 mg/day 
applied nightly .Prior to ABPM sessions, the application site should not 
be on the arm used for the blood pressure cuff.
Packaging and LabelingStudy intervention will be provided in boxes. Each b ox will be labeled as 
required per country requirements.
Manufacturer Allergan
6.2. Preparation/Handling/Storage/Accountability
1.The investigator or designee  must confirm appropriate temperature conditions have been 
maintained during transit for all study intervention received and an y discrepancies are 
reported and resolved before use of the stud y intervention.
2.Only  participants enrolled in the study  may  receive study  intervention , and only  
authorized site staf f may  supply  or administer study  intervention . All study  intervention 
must be stored in a secure , environmentall y controlled , and monitored (manual or 
automated) area in accordance with the labeled  storage conditions with access limited to 
the investigator and authorized site staf f.
3.The investigator , institution, or the head of the medical institution (where applicable) is 
responsible for stud y intervention accountability , reconciliation, and record maintenance 
(ie, receipt, reconciliation , and final disposition records) . 
4.Further guidance and information for the final disposition of unused study  interventions 
will be provided by  [CONTACT_456] .
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827604] -T-01 -01 v3.06.3. Measures to Minimize Bias: Randomization and Blinding
This is an open -label, single -arm stud y. No blinding of assigned study intervent ion will occur.
Each participant who provides informed consent will be assigned a partic ipant ID number. 
Participant ID numbers will be unique [ADDRESS_827605] of the 3 -digit protocol number (402 ), 5-digit site number, and [ADDRESS_827606] that specifies the amount of study 
intervention dispensed to each participant .
6.5. Concomitant Therapy
Any medication or vaccine (including over -the-counter, prescription medicines, vitamins, herbal 
supplements, and/or cannabis or other specific categories of interest ) that the participant is 
receiving at the time of enrollment or receiv es during the stud y must be recorded along with:
Indication
Dates of administration including start and end dates
Dosage information including dose and frequency
At screening , during the study ,and at EOS ,study  staff will question each participant specifi cally 
on the use of concomitant medications. Study  staff must notify  the sponsor immediately  if a 
participant consumes an y concomitant medications not permitted by [CONTACT_760]. Participants
who admit to using prohibited concomitant medications may  be disc ontinued from the stud y at 
the discretion of the investigator or the s ponsor.
Concurrent chronic medications, such as medications for h ypertension, h yperlipi[INVESTIGATOR_035], diabetes, 
and anticoagulation should be administered in dosages with no intention of changin g for the 
duration of the study .
6.5.1. Prohibited Interventions and Washout Before the Study
Over the counter or herbal preparations containing testosterone are prohibited 7 day s or 
5half-lives (whichever is longer) before screening and throughout the study.
The decision to administer a prohibited medication/intervention during the study period is done 
with the safet y of the study participant as the primary consideration. When possible, the sponsor 
is to be notified before the prohibited medication/intervention is administered.
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827607] -T-01 -01 v3.06.5.2. Permitted Interventions
Therap y considered necessary  for the participant’s welfare may  be given at the discretion of the 
investigator. If the permissibility  of a specific medication/ intervention is in question, please 
contact [CONTACT_456].
The sponsor or designee should be contact[CONTACT_43205] y questions regarding concomitant or 
prior therap y.
Any medication taken during the stud y between the date of the first dose of study intervention
and the date of the EOS visit will be recorded in the eCRF as a concomitant medication; any  
medication started after the EOS visit will not be considered a concomitant medication and 
should not be captured in the eCRF.
6.5.3. Rescue Medicine
Rescue medicine is n ot applicable .
6.5.4. Prohibited Interventions During the Study
Participants must abstain from taking prescription or nonprescription drugs (including drugs 
containing testosterone, vitamins ,and dietary  or he rbal supplements) within 7 day s or 5 
half-lives (whichever is longer) before the start of stu dy intervention until completion of the 
follow -up visit, unless, in the opi[INVESTIGATOR_2511] i nvestigator and sponsor, the medication will not 
interfere with the study .
6.6. Dose Modification
All participants will initially  receive a standard starting dose of Androde rm of 4mg/day  which 
will be applied nightl y at approximately 2200, starting on Visit 1. At Visit 2, a fasting morning 
testosterone concentration will be measured. Vis it 3 will occur when results of the fasting 
testosterone concentration are available. Par ticipants with a testosterone concentration 
<400ng/dL will require an increase indose to6 mg/day  (one 4 mg/day system and one 
2mg/day  system) applied nightly . Participants with a testosterone concentration of > 930 ng/dL
will require a decrease in dose to 2 mg/day  (one 2 mg/day  system) applied nightly . All others 
will remain on 4 mg/day .
If all doses of stud y intervention are well- tolerated, the total duration of participation in the study  
will be approximately  19 weeks ( 3 weeks for screening, plus 16 weeks [Day 1 through 
Visit6/EOS ]of intervention therap y).
6.7. Intervention after the End of the Study
No intervention will be given after the EOS.
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827608] -T-01 -01 v3.07. Discontinuation of Study Intervention and Participant
Discontinuation/ Withdrawal
A premature discontinuation will occur if a participant who signs the ICF and receives study  
intervention ceases participation in the study , regardless of circumstances, before the completion 
of the protocol -defined study  procedures.
Notification of early participant discontinuation from the study  and the reason for 
discontinuation will be made to the sponsor and will be clearl y documented.
Reasons for discontinuation from the study  treatment and/or the study  may  include the following
commonly  used or othe r acceptable terms :
Comm only Used T erms Other Acceptable T erms
Adverse event Death
Com pleted Disease relapse
Lack of efficacy Technical problems
Lost to follow -up
Non-compliance with study drug
Other
Physician decision
Protocol deviation
Screen failure
Site terminated by [CONTACT_268331]
7.1. Discontinuation ofStudy Intervention
See the SoA for data to be collected at the time of intervention discontinuation and follow -up and 
for an y further evaluations that need to be completed .
If feasible, 24 -hour ABPM should be collected at the time of intervention discontinuation.
7.2. Participant Discontinuation/ Withdrawal from the Study
A participant  may with draw from the stud y at an y time at his own request, or may  be 
withdrawn at an y time at the discretion of the investigator  for safety , behavioral , 
compliance, or administrative reasons .
If the participant  withdraws consent  for disclos ure of future informati on, the s ponsor may  
retain and continue to use an y data collected before such a withdrawal of consent .
If a participant  withdraws from the study , he may request destruction of any  samples taken 
and not tested , and the investigator must document this in the site study  records .
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827609] be taken ifa participant fails to return for a required study  visit:
The site must attempt to contact [CONTACT_47995] m issed visit as soon as 
possible and counsel the participant on the importance of maintaini ng the assigned visit 
schedule and ascertain whether the participant  wishes to and/or should continue in the 
study .
Before a  participant  is deemed lost to follow -up, the investigator or designee must make 
every  effort to regain contact [CONTACT_6635] (where possible, 3 telephone calls , and if 
necessary , a certified letter to the participant ’s last known mailing address or local 
equivalent methods). These contact [CONTACT_9145] ’s 
medical record .
Should the participant continue to be unreachable, he will be considered to have 
withdrawn from the study .
Discontinuation of specific sites , or of the study  as a whole , are handled as part of 
Appendix 1.
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827610] -T-01 -01 v3.08. Study Assessments and Procedu res
Study  procedures and their timing are summarized in the SoA. Protocol waiver s or 
exemptions are not allowed.
Immediate  safety  concerns  should be discussed with the s ponsor immediately  upon 
occurrence or awareness to determine if the participant should continue or discontinue 
study  intervention .
Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study  conduct.
All screening evaluations must be completed and reviewed to confirm that  potential 
participant s meet all eligibility  criteria. The investigator will maintain a screening log to 
record details of all participant s screened and to confirm eligibility  or record reasons for 
screening failure, as applicable.
Procedures conducted as part of the  participant’ s routine clinical management (eg, blood 
count) and obtained before signing of the ICF  may be utilized for screening or baseline 
purposes provided the procedure s met the protocol -specified  criteria and were performed 
within the timeframe defin ed in the SoA.
8.1. Efficacy Assessments
8.1.1. ABPM Assessments
BP parameters , including SBP, DBP, MAP, pulse pressure, and heart rate will be collected b y 
24-hour ABPM according to the SoA. The ABPM device is a validated device, recommended b y 
relevant, well -known international hypertension societies and is FDA approved . All ABPM 
measurement swill be done using the same make and model ABPM device supplied by  [CONTACT_621761] , and for each participant, the same device used at baseline must be used for 
postbaseline measurements. BP parameters will be collected at a minimum of [ADDRESS_827611] 70% of expected measurements (33 valid during the 24 hours); 20 valid 
awake (0900 to 2100); and 7 valid asleep (0100 to0600) ( O’Brien 2013 ).The time of the last 
dose of Androderm prior to the ABPM measurements will be recorded.
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827612] -T-01 -01 v3.0Term Definition
Baseline ABPM Any assessment recorded during the approximately 24 -hour period starting on S creening 
Visit 3; after the ABPM device is applied, through V isit 1, when the ABPM device is 
removed
Week 16 (End of 
study intervention )Any assessment recorded during the approximately 24 -hour period starting on Visit 5, 
after the ABPM device is applied, through V isit6/EOS /ET, when the ABPM device is 
removed
24-hour ABPM Any assessment recorded at the specified analysis timepoint ( baseline, Week 16 ) during 
the approximately 24 -hour period after the ABPM device is applied through when the 
ABPM device is removed
DaytimeABPM Any assessment recorded between 0900 and 2100 on either:
the day the ABPM device is applied
the day the ABPM device is removed
Night -time ABPM Any assessment recorded between 0100 and 0600 on either:
the day the ABPM device is applied
the day the ABPM device is removed
Hours 0 through 23 For each Hour X, any assessment recorded betw een X X00 and X X59, on either:
the day the ABPM device is applied
the day the ABPM device is removed
8.2. Safety Assessments
Planned timepoints for all safet y assessments are provided in the SoA.
8.2.1. Physical Examinations
A complete ph ysical examination will include, at a minimum, assessments of the 
cardiovascular , respi[INVESTIGATOR_696] , gastrointestinal and neurol ogical  systems.  Height and w eight 
will also be measured and recorded.
Investigators should pay  special attention to clinical signs related to previous serious 
illnesses.
Physical exam ination s should be completed b y a professionall y trained ph ysician or health 
professional listed on F ormFDA 1572 and licensed to perform ph ysical examinations .
8.2.2. Vital Signs
Vital signs will be assessed as follows:
Oral temperature, and triplicate heart  rate and cuff BP will be assessed.
BP and pulse measurements will be assessed sitting  with a completel y automated device. 
Manual techniques will be used onl y if an automated device is not available.
BP and pulse measurements should be preceded by [CONTACT_2669] [ADDRESS_827613] for the 
participant in a quiet setting without distractions (eg, te levision, cell phones).
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827614] -T-01 -01 v3.0Vital signs (to be taken before blood collection for laboratory tests) will consist of 3 pulse 
and 3 BP measurements ([ADDRESS_827615] 
1minute). All BP readings will be recorded on  the eCRF.
8.2.3. Clinical Safety Laboratory Assessments
See Appendix [ADDRESS_827616] of clinical laboratory tests to be performed and the SoA for the 
timing and fre quency .
At screening, the investigator or sub investigator will assess the clinical significance of an y 
values outside the reference ranges provided b y the laboratory , and participants with 
abnormalities judged to be clinically significant will be excluded from the study .
The investigator must review the laboratory  report, document this review , and record an y 
clinically  relevant changes occurring during the study  in the AE section of the e CRF. The 
laboratory  reports must be filed with the source documents. Clinically  significant 
abnormal laboratory  findings are those that are not associated with the underly ing disease, 
unless judged b y the investigator to be more severe than expected for the participant ’s 
condition.
All laboratory  tests with values considered clinically  significant  during participation in the 
study  should be repeated until the values return to normal or baseline  or are no longer 
considered clinically  significant by  [CONTACT_093] .
oIf such values do not return to normal/baseline within a period of time judged 
reasonable b y the investiga tor, the etiology  should be identified and the sponsor  
notified.
oAll protocol -required laboratory  assessments, as defined in Appendix 2, must be 
conducted in accordance with the laboratory manual and the SoA.
oIf laboratory  values from non -protocol -specified laboratory  assessments performed at 
a local laboratory  require a change in participant management or are considered 
clinically  significant b y the investi gator (eg , SAE or AE or dose modification), then 
the results must be recorded in the AE eCRF.
8.3. Adverse Events and Serious Adverse Events
The definitions of an AEor SAE can be found in Appendix 3.
AEs will be reported b y the participant (or, when appropriate, b y a caregiver, surrogate, or the 
participant’ s legall y authorized representative).
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events th at meet the definition of an AEor SAE and remain responsible for following 
up AEs that are serious, considered re lated to the study  intervention or study  procedures, or that 
caused the participant to discontinue the study  intervention or study  (see Sectio n 7).
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827617] -T-01 -01 v3.08.3.1. Time Period and Frequency for Collecting AEand SAE Information
All AEs/ SAEs from the signing of the ICF until the follow -up visit will be c ollected at the 
timepoints specified in the SoA (Section 1.3), and as observed or reported spontaneously  by 
[CONTACT_171579] .
Medical occurrences that begin before the start of stud y intervention ,but after obtaining 
informed consent will be recorded in the AE section of the eCRFand will be considered 
pretreatment AEs .
All SAEs will be recorded and reported to the sponsor or designee within [ADDRESS_827618] within 30 day s of the final protocol -defined study  visit.
Investigators are no t obligated to activel y seek AEor SAE information after conclusion of the 
study  participation . However, if the investigator learns of an y SAE , including a death, at an y 
time after a participant has been discharged from the study , and he/she considers the event to be 
reasonabl y related to the study intervention or study participation, the investigator must promptly 
notify  the sponsor .
The method of recording, evaluating, and assessing causality of AEsand SAE s and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3.
8.3.2. Method of Detecting AEs and SAEs
Care will be taken not to introduce bias when detecting AEs and/or SAEs . Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences .
8.3.3. Follow -up of AEs and SAEs
After the initi al AE/SAE report, th e investigator is required to proactivel y follow each participant 
at subsequent visits/contacts. All SAEs will be followed until resolution, stabiliz ation , the event 
is otherwise explained, or the participant is lost to follow -up (as defined in Sectio n 7.3).
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested b ythesponsor or 
designee to elucidate the nature and/or causalit y of the AEor SAE as full y as possible. This may 
include additional laboratory  tests or investigations, histopathological examinations, or 
consultation with other health care professionals.
If a participant dies during participation in the study  or during a recognized follow -up period, the 
investigator will provide the sponsor or designee with a cop y of an y postmortem findings 
including histopathology .
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827619] ed in the originally  completed eCRF.
The investigator will submit any  updated SAE data tosponsor or designee within 24 hours of 
receipt of the information.
8.3.4. Regulatory Reporting Requirements for SAEs
Prompt notification by  [CONTACT_11012] a
n SAE  is essential so that legal 
obligations and ethical responsibilities towards the safet y of participants and the safet y of 
a study  intervention  under clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the l ocal regulatory  authority  and 
other regulatory  agencies about the safet y of a study  intervention  under clinical 
investigation. The sponsor will comply  with country -specific regulatory  requirements 
relating to safet y reporting to the regulatory authority , IRBs/IECs, and investigators.
An investigator who receives an investigator safety report describing a n SAE  or other 
specific safet y information (eg, summary or listing of SAEs ) from the sponsor will review 
and then file it along with the package insert and will notify  the IRB/IEC, if appropriate 
according to local requirements.
Investigator safety  reports must be prepared for S[LOCATION_003]Rs according to local regulatory  
requirements and sponsor policy and forwarded to investigators as necessary .
8.3.5. Medication Errors
Medication error refers to any unintended error in the dosing and/or administration of the study 
intervention as per instructions in the protocol. Medication errors generall y fall into 4 categories 
as follows:
Wrong study  drug/device
Wrong dose (including dosing regimen, strength, form, concentration, amount)
Wrong route of administration , including wrong site of administration (eg, wrong ey e)
Wrong participant (ie, not administered to the intended participant)
Medication errors include occurrences of overd ose and underdose of the study  intervention .
Overdose: Unintentional administration of a quantity  of the stud y intervention given per 
administration or per day that is above the maximum recommended dose according to the 
reference safet y information or prot ocol for the stu dy intervention . This also takes into account 
cumulative effects due to overdose. In this stud y, overdose is defined as taking more than the 
assigned dose of stud y intervention.
Underdose: Unintentional administration of a quantity  of the s tudy intervention given per 
administration or per day that is under the minimum recommended dose according to the 
reference safet y information or protocol. In this study , underdose is defined as taking less than 
the assigned dose of study intervention.
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827620]
1.Potential Hy ’s Law cases :
ALT or AST ≥ 3 × ULN and 
Total Bilirubin ≥ 2 × ULN and 
Alkaline Phosphatase < 2 × ULN 
Anytime from the time the participant signs the ICF for the trial ,until the final follow -up visit, 
investigators will notify  the sponsor immediately  when all the above criteria have been met. A 
potential Hy ’s law case will be sent directl y to the sponsor b y emailing 
IR-clinical- [EMAIL_3235] on an AE of Special I nterest Form along with the SAE Report
Form as soon as possible (within 24 hours of learning of the poten tial Hy ’s Law). The CRF for 
potential Hy ’s law cases will be completed within 7calendar day s. Every  effort to determine the 
cause of the liver enz yme abnormalities will be made, and close monitoring will be initiated in 
conjunction with the medical monitor and in accordance with the F DA “Guidance for Industry : 
Drug -Induced Liver Injury: Premarketing Clinical Evaluation” July  2009. 
2.Prostate events: 
Lower urinary  tract sy mptoms of prostatic  hyperplasia
Potential lower urinary  tract sy mptoms of prostatic hy perplasia will be sent directly to the 
sponsor by  [CONTACT_134870] -clinical -[EMAIL_3235] on an AE of Special Interest Form along 
with the SAE Report Form as soon as possible (within 24 hours of learning of the event ). The 
CRF for lower urinary  tract sy mptoms of prostatic hy perplasia will be completed within 
7calendar day s.
8.4. Treatment of Overdose
For this study , any  dose of Androderm greater than the assigned dose within a 24 -hour time 
period will be considered an overdose.
Allergan does not recommend specific intervention for an overdose
In the event of an overdose, the investigator should:
1.Contact [CONTACT_621762] y.
2.Closely  monitor the participant for an y AE/SAE and /orlaboratory abnormalities .
3.Obtain a plasma sample for PK anal ysis if requested by  [CONTACT_268334] y physician
(determined on a case -by-case basis).
4.Document the quantit y of the excess dose as well as the duration of the ov erdose in the 
eCRF.
Decisions regarding dose interruptions or modifications will be made by [CONTACT_621763] y physician based o n the clinical evaluation of the participant.
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827621] -T-01 -01 v3.08.5. Pharmacok inetics
Fasting morning serum total testosterone concentrations will be measured prior to ABPM device 
placement during the screening period on Screening Visit 3 (Day  -3 to -1) and at Visit 5 
(Day 112). The time of sample collection and ABPM device placement should be noted.
Fasting s erum total testosterone concentrations will also be measured on Visit 2 (Day 14) and 
Visit 4 (Day 56), approximately  8 to 12 hours after application of the nightly dose on the 
previous night.
The serum total testosterone concentrations will be determined usi ng a validated bioanal ytical 
methodology .
8.6. Pharmacodynamics
Pharmacod ynamic parameters are not evaluated in this study .
8.7. Genetics
Genetics are not evaluated in this study .
8.8. Biomark ersand Other Assessments
Biomarkers are not evaluated in this study .
8.9. Health Ec onomic sOR Medical Resource Utilization and Health 
Economic s
Health economics/Medical resource utilization and health e conomics parameters are not 
evaluated in this study .
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827622] -T-01 -01 v3.09. Statistical Considerations
9.1. Statistical Hypotheses
The null and alternative hy potheses for change from baseline in 24 -hour average SBP obtained at 
baseline and Week 16 (Week 16 minus baseline) are as follows:
H0: mE -mB ≥ 3.0 versus H a: mE -mB < 3.[ADDRESS_827623] deviation of 10.0 mmHg, 120 participants with available ABPM data at Week 16 
will be required to provide 90% power to reject the null hypothesis at the 2 sided 5% 
significance level. Assuming a 25% dropout rate, 150 participants will be enrolled. 
Approximately  300 participants will be screened ,to achieve 150 enrolled who receive 
≥ 1administration of study intervention, for an estimated total of [ADDRESS_827624] of participants asdefined below :
The mITT population includes all participants with valid baseline ABPM session,  who 
received ≥ 1 administration of study intervention , ≥[ADDRESS_827625] 85% compliance to stud y intervention for the 
duration of the study .
The safety population include s all treated participants who receiv e ≥ 1 administration of 
study  intervention.  
The P K population include s all participants who have ev aluable testosterone 
concentrations .
9.4. Statistical Analyses
The SAP will be developed and finalized before database lock and will describe the participant 
populations to be included in the anal yses and procedures for accounting for missing, unused, 
and spurious data. This section is a summary  of the planned statistical analyses of the primary 
and secondary  endpoints .
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827626] application of study  intervention. All statistical tests will 
be 2-sided hypothesis tests performed at the 5% level of significance for main effects. All C Is 
will be 2 -sided 95% CI s, unless stated otherwise. No multiple comparison procedures will be 
applied.
[IP_ADDRESS]. Analysis Endpoints
The primary  and secondary  efficacy  endpoints are listed below and anal yses will be defined in 
the following sections. All analy ses for other efficacy  endpoints listed below will be defined in 
the SAP.
Primary  efficacy  endpoint :
Change from baseline in 24 -hour average SBP  obtained at Week 16
Secondary  efficacy  endpoints:
Change  from baseline  in 24 -hour average DBP , MAP , pulse pressure, and heart rate 
obtained at W eek 16
Other efficacy  endpoints :
Change  from baseline  in day time average SBP , DBP , MAP , pulse pressure, and heart rate 
obtained at W eek 16
Change  from baseline  in night
-time average SBP, DBP , MAP , pulse pressure, and heart 
rate obtained at Week 16
Change from baseline over time (hourl y average) by [CONTACT_621764]: SBP , DBP , MAP , pulse pressure, and heart rate
The status (y es or no) of participants with new anti-hypertensive medications
The status (y es or no) of participants with dose increases in anti -hypertensive medications
Outlier responder for participants meeting SBP ≥ 160 mmHg for 24 -hour average
Outlier responder for participants meeting  SBP change f rom baseline  ≥ 20 mm Hg for 
24-hour average
Outlier responder for participants meeting  DBP  ≥ 100 mmHg for 24 -hour average
Outlier responder for participants meeting  DBP  change from baseline  ≥ 15 mm Hg for 
24-hour average
Status (yes/no) of participants with normalized testosterone concentrations at Week 16
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827627] -T-01 -01 v3.[IP_ADDRESS]. Primary Analyses
Continuous descriptive statistics (n, mean, SD, median, min, max, Q1 and Q3) of [ADDRESS_827628], along with a 2 -sided 95% CI. 
If the upper bound of the two -sided 95% CI is less than 3.0, the alternative hypothesis of 
excluding an increase of 3 mm Hg in SBP will be inferred.
[IP_ADDRESS]. Secondary Analys es
Continuous secondary  endpoints will be summarized by  [CONTACT_9086] (n, mean, SD, 
median, min, max, Q1 and Q3).
Categorical secondary  and other endpoints will be summarized by  [CONTACT_621765].
9.4.2. Safety Analyses
The safet y analysis will be performed using th e safety  population and will be fully  defined in the 
SAP. The safet y parameters will include AEs , clinical laboratory ,andvital sign s. For each of the 
clinical laboratory  and vital sign sparameters, the last nonmissing safet y assessment before the 
first dose of study  intervention will be used as the baseline for all anal yses of that safet y 
parameter.
[IP_ADDRESS]. Adverse Events
An AEwill be considered a TEAEifthe AE began or worsened (increased in s everity  or became 
serious) on or after the date (and time, if known) of the first dose of stud y intervention. However, 
an AE that occurs more than [ADDRESS_827629] related 
occurrence for the summarization sby [CONTACT_621766] .
Summary  tables will be provided for participants with TESAEs and participants with TEAEs
leading to discontinuation if these occurred in 5 or more participants. L isting sof all AEs, SAEs , 
and AEs leading to discontinuation by  [CONTACT_217664].
The definitions of an AEand SAE can be found in Appendix 3.
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827630] -T-01 -01 v3.[IP_ADDRESS]. Clinical Laboratory Assessments
Descriptive statistics for clinical laboratory values (in SI  units) at baseline (screening) and 
changes from baseline at each assessment will be presented for each clinical laboratory  
assessment.
The criteria for PCS laboratory  values will be detailed in the SAP. The number and percentage of 
participants who have PCS postbaseline clinical laboratory values will be tabulated at each 
assessment . The percentages will be calculated relative to the number of participants who have 
available non- PCS baseline values and at least [ADDRESS_827631] 1 PCS postbaseline value. A supportive listing of 
participants with PCS postbaseline values will be provided for the safety population. 
[IP_ADDRESS]. Vital Signs
Descriptive statistics for vital signs (s ystolic and diastolic cuff BP, heart rate, weight, and 
temperature) at baseline (screening) and changes from baseline at each assessment will be 
presented .
Vital signs values will be considered to be PCS if they  meet both the observed -value criteria and 
the change -from -baseline -value criteria that will be detailed in the SAP. The number and 
percentage of participants who have PCS postbaseline vital signsvalues will be tabulated for 
each assessment . The percentages will be calculated relative to the number of participants who 
have available non -PCS basel ine values and at least [ADDRESS_827632] 1 PCS postbaseline value. A supportive 
listing of participants with PCS postbaseline values will be provided for the safety population.
9.4.3. PKAnalyses
Fasting morning serum total testosterone concentrations will be measured prior to ABPM device 
placement during the screening period on Screening Visit 3 (Day -3 to -1) and at Visit 5 
(Day 112). The time of sample collection and ABPM device placement should be noted.
Fasting s erum total testosterone concentrations will also be measured on Vi sit 2 (Day  14) and 
Visit 4 (Day 56), approximately  8 to 12 hours after application of the nightly dose on the 
previous night.
Concentrations below the limit of quantitation will be treated as 0 for all PK calculations. 
Descriptive statistics for testostero ne concentrations will be provided at each sampling timepoint 
for all participants in the PK population. Details of the statistical analyses of PK data will be 
described in the anal ysis plan finalized prior to database lock. 
9.4.4. Other Analyses
In addition to the anal ysis method described in Section 9.4, all exploratory anal yses will be 
described in a separate SAP. Graphical summaries may  include:
Box pl ot of hourly  average for both SB P and DBP  at baseline and at endpoint
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827633] -T-01 -01 v3.0Cumulative distribution function curves of 24 -hour average SBP  and DBP  at baseline and 
postbaseline
Forest plots for change from baseline SBP  and DBP  of day time, night -time and 24 -hour 
average
[IP_ADDRESS]. Subgroup Analyses
Sensitivity  analy ses on the primary  endpoint, secondary  endpoints, and graphical summaries will 
be conducted on the following subgroups:
Participants without baseline medical history of hypertension
Participants with treated baseline  medical history  of hy pertension
Participants with untreated baseline medical history of h ypertension
9.5. Interim Analyses
There is no interim analysis planned for the stud y.
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827634] -T-01 -01 v3.010. Supporting Documentation and Operational Considerations
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827635] -T-01 -01 v3.010.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with  the following :
oConsensus ethic al principles derived from international guidelines including the 
CIOMS In ternational Ethical Guidelines
oApplicable ICH /ISO GCP  guidelines
oApplicable laws and regulations
The protocol, protocol amendments, I CF, package insert , and other relevant documents 
(eg, advertisements) must be submitted to an I RB/IEC b y the investigator a nd reviewed 
and approved b y the IRB/I EC before the stud y is initiated.
Any amendments to the protocol will require IRB/I EC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate 
hazard to study  participants. 
The investigator will be responsible for the following:
oProviding written summaries of the status of the study to the IRB/ IEC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  [CONTACT_1201]/ IEC
oNotify ing the IRB/IEC of SAE s or other significant safet y findings as required by 
[CONTACT_1744]/IEC procedures
oProviding oversight of the  overall conduct of the study  by [CONTACT_621767], for example  21 CFR, I CH guidelines, 
the IRB/IEC, and European regulation 536/2014 for clinical studies (if  applicable)
10.1.2. Financial Disclosure
Investigators and subinvestigators will provide the sponsor with sufficient, accurate financial 
information as requested to allo w the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authorities. I nvestigators are 
responsible for providing information on financial interests during the course of the stud y and for 
1 year after completion of the study .
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827636] -T-01 -01 v3.010.1.3. Informed Consent Process
The investigator or his/her representative will explain the nature of the study to the 
participant or his/her legally  authorized representative and answer all questions regarding 
the study . 
Participants must be informed that their participation is voluntary . Participants will be 
required to sign a statement of  informed consent that meets the requirements of 21  CFR 
50, local regulations, ICH guidelines, HI PAA requirements , where applicable , and the 
IRB/IEC or stud y center . 
The medical record must include a statement that signed  informed consent was obtained 
before the participant was enrolled in the study and the date the signed  consent was 
obtained. The authorized person obtaining the informed consent must also sign the ICF .
Participants must be re -consented to the most current version of the ICF(s) during their 
participation in the study . 
A copy of the ICF(s)  must be provided to the participant or the participant’ s legally  
authorized represent ative. 
10.1.4. Data Protection
Participants will be assigned a unique identifier by [CONTACT_456] . Any participant records or 
datasets that are transferred to the sponsor will contain the identifier only; any identifiable 
participant information will only  be transf erred in accordance with the signed Informed 
Consent provisions.
The participant must be informed that his personal study -related data will be used b y the 
sponsor in accordance with local privacy  and data protection laws. The level of disclosure 
must also be explained to the participant who will be required to give consent for their 
personal data to be used as described in the informed consent.
The participant must be informed that his medical records may be examined by  [CONTACT_160439] , by 
[CONTACT_6667]/IEC members, and b y inspectors from regulatory authorities.
Management of privacy  incidents relating to clinical trial participant personal data, as well as 
handling of data particip ant rights requests (if applicable), should be handled in accordance 
with the agreed upon CT A provisions.
10.1.5. Dissemination of Clinical Study Data
All data generated in this study  are the propert y of the sponsor. An integrated clinical and 
statistical report will be prepared at the completion of the study.
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827637] -T-01 -01 v3.010.1.6. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponso r or designee electronically  (eg, laboratory  data). The investi gator is 
responsible for verify ing that data entries are accurate and correct by  [CONTACT_20010] .
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF .
The investi gator must permit study- related monitoring, audits, IRB/IEC review , and 
regulatory  agency  inspections and provide direct access to source data documents.
The sponsor or designee is responsible for the data management of this study including 
quality  checkin g of the data.
The sponsor assumes accountability  for actions dele gated to other individuals (eg , Contract 
Research Organizations).
Study  monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by  [CONTACT_42535], complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study is 
being conducted in accordance with the currently approved protocol and any other stud y 
agreements, I CH GCP , and all applicable regulatory  requirements.
Records and documents, including signed ICFs, pertaining to the conduct of this study must 
be retained b y the investigator as stated in the clinical trial agreement. No records may be 
destroy ed during the  retention period without the written approval of the sponsor . No records 
may be transferred to another party without written notification to the sponsor .
10.1.7. Source Documents
Source documents provide evidence for the existence of the participant and substanti ate 
the integrit y of the data collected. Source documents are filed by [CONTACT_093] ’s site.
Data reported on the CRF or entered in the eCRF  that are transcribed from source 
documents must be consistent with the source documents or the discrepancies mus t be 
explained. The investigator may need to request previous medical records or transfer 
records, depending on the stud y. Also, current medical records must be available.
Source data are defined as: original documents, data, and records (eg, hospi[INVESTIGATOR_93476], 
clinical and office charts, diaries or evaluation checklists, pharmacy dispensing records,  
recorded data from automated instruments, copi[INVESTIGATOR_14848], microfiche, photographic negativ es, 
microfilm or magnetic media, X -rays, participant files, and records kept at the pharmacy , 
at the laboratories, and at medico -technical departments involved in the clinical study). 
These records include, but are not limited to, original signed and dated  consent forms, 
relevant observations including records of AEs, and records of all exposure to study  
intervention.
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827638] been collected and a study -site closure visit has been performed.
The investigator may  initiate study -site closure at any  time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.
Reasons for the earl y closure of a stud y site b y the sponsor or investigator may include but are 
not limited t o:
Failure of the investigator to comply  with the protocol, the requirements of the I RB/IEC or 
local health authorities, the sponsor's procedures, or GCP  guidelines
Inadequate recruitment of participants b y the investigator
Discontinuation of further study  intervention development
If the stud y is prematurely terminated or suspended, the spo nsor shall promptly  inform the 
investigators, the IECs/IRBs, the regulatory authorities, and an y contract research organization(s) 
used in the study  of the reason for ter mination or suspension, as specified by  [CONTACT_281154]. The investigator shall promptly  inform the participant and should assure 
appropriate participant therap y and/or follow -up. If a premature termination or suspension 
occurs, the sponsor shall remain responsible for providing resources to fulfill the protocol 
obligations and existing agreements for follow -up of participants enrolled in the study , and each 
investigator or authorized designee shall promptly inform enrolled participan ts, if applicable.
10.1.9. Publication Policy
Allergan as the sponsor has proprietary interest in this study . Authorship and manuscript 
composition will reflect joint cooperation between multiple investigators and sites and 
Allergan personnel. Authorship will be e stablished prior to the writing of the manuscript. 
As this study  involves multiple centers, no individual publications will be allowed prior to 
completion of the final report of the multicenter study except as agreed with Allergan.
The sponsor will comply  with the requirements for publication of study  results. I n 
accordance with standard editorial and ethical practice, the sponsor will generall y support  
publication of multicenter studies only in their entirety and not as individual site data.
Authorship wil l be determined by  [CONTACT_11403] I nternational 
Committee  of Medical Journal Editors authorship requirements.
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827639] with the investigator and his/her 
research staff and will conduct regular monitoring visits by[CONTACT_621768]. Protocol deviations 
will be discussed with the investigator upon identification. Significant protocol deviations will be 
reported to the IRB/ IEC according to the I RB/IEC’s reporting requirements.
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827640] -T-01 -01 v3.010.2. Appendix 2: Clinical Laboratory Tests
The tests detailed in Table10-1 will be performed by  [CONTACT_2237] . 
Protocol -specific requirements for inc lusion or exclusion of participants are detailed in 
Section 5 of the protocol.
Additional tests may  be performed at an y time during the stud y as determined necessary  
by [CONTACT_43215] .
Table 10-1 Protocol -required Safety Laboratory Assessments
Laboratory 
AssessmentsParam eters
Hem atology Platelet count RBC indices :
MCV
MCH
MCHC
%ReticulocytesWBC count with differential 
(absolute) :
Neutrophils
Lymphocytes
Monocytes
Eosinophils
BasophilsRBC count
Hem oglobin
Hem atocrit
PT
INR
Clinical Chemistry BUN Potassium AST Total, direct and 
indirect bilirubin
Creatinine Sodium ALT Total protein
Glucose , fasting Calcium Alkaline 
phosphataseCholesterol, 
chloride, albumin
HbA1c PSA Fasting morning 
total testosterone
Prolactin
Routine Urinalysis Specific gravity
pH, glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocyte 
esterase by [CONTACT_5230]
Microscopic examination (if blood or protein is abnormal)
Investigators must document their review of each laboratory safet y report.
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827641] -T-01 -01 v3.010.4. Appendix 4: Abbreviations
Abbreviation Definition
ABPM ambulatory blood pressure monitoring
AE adverse event
AESI adverse event of special interest
ALT alanine aminotransferase
AST aspartate aminotransferase
BMI body mass index
BP blood pressure
BUN blood urea nitrogen
CDISC Clinical Data Interchange Standards Consortium
CFR Code of Federal Regulations
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CONSORT Consolidated Standards of Reporting Trials
CRF case report form
DBP diastolic blood pressure
DHEA dehydroepi[INVESTIGATOR_621749]1c hemoglobin A1c
ICF informed consent form
ICH International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use
ID identification
IEC Independent Ethics Committee
INR international normalized ratio
I-PSS International Prostate Symptom Score
IRB Internal Revie w Board
ISO International Organization for Standardization
IUD intrauterine device
IUS intrauterine system
MAP mean arterial pressure
MCH mean corpuscular hemoglobin
MCHC mean corpuscular hemoglobin concentration
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827642] -T-01 -01 v3.0Abbreviation Definition
MCV mean corpuscular volume
mITT modified intent -to-treat
N/A not applicable
NCI National Cancer Institute
PCS potentially clinically significant
PK pharmacokinetic
PSA prostate specific antigen
PT prothrombin time
Q1 quartile [ADDRESS_827643] upper limit of normal
V1 Intervention Period Visit 1
V2 Intervention Period Visit 2
V3 Intervention Period Visit 3
V4 Intervention Period Visit 4
V5 Intervention Period Visit 5
V6 Intervention Period Visit 6
WBC white blood cell
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827644] -T-01 -01 v3.010.5. Appendix 5: Standard Discontinuation Criteria
This table provides participant discontinuation criteria for this protocol. CDISC terminology  is 
used, and thus subject or patient is used instead of participant (as used elsewhere in this 
protocol ).These terms are interchangeable.  
CDISC Submission V alue CDISC Definition
Adverse event Any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product and 
which does not necessarily have a causal relationship with this 
treatment. An AE can therefore be any unintended sign (including 
an abn ormal laboratory finding), symptom, or disease temporally 
associated with the use of a medicinal (investigational) product, 
whether or not related to the medicinal (investigational) product. 
For further information, see the ICH Guideline for Clinical Safet y 
Data Management: Definitions and Standards for Expedited 
Reporting (modified from ICH E2A )Synonyms: side effect, 
adverse experience. See also serious adverse event, serious adverse 
experience. (CDISC glossary)
Com pleted To possess every necessary or normal part or component or step; 
having come or been brought to a conclusion (NCI)
Death The absence of life or state of being dead (NCI)
Disease relapse The return of a disease after a period of remission
Lack of efficacy The lack of expected or desir ed effect related to a therapy (NCI)
Lost to follow -up The loss or lack of continuation of a subject to follow -up
Non-compliance with study drug An indication that a subject has not agreed with or follow ed the 
instructions related to the study medication (NCI)
Other Different than the one(s) previously specified or mentioned (NCI)
Physician decision A position, opi[INVESTIGATOR_1649] ,or judgment reached after consideration by a 
physician with reference to subject (NCI)
Protocol deviation An event or decision that stands in contrast to the guidelines set out 
by [CONTACT_760] (NCI)
Screen failure The potential subject who does not meet one or more criteria 
required for participation in a trial
Site terminated by [CONTACT_78588] a clinical study was stoppe d at a particular site 
by [CONTACT_23662] (NCI)
Study terminated by [CONTACT_78588] a clinical study was stopped by [CONTACT_23662] 
(NCI)
Technical problems A problem with some technical aspect of a clinical study, usually 
related to an instrument (NCI)
Withdraw al by [CONTACT_78589] a study participant has removed itself from the 
study (NCI)
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827645] -T-01 -01 v3.010.6. Appendix 6: Study Tabular Summary
This table is intended for use in posting study information to registries (eg, ClinicalTrials.gov).
Param eter Gr oup Param eter Value
Trial information Trial Title A Phase IV, Multi -center, Open -label, 
Single -arm 24-hour Ambulatory Blood 
Pressure Monitoring (ABPM) Study of 
16 Weeks Treatment with Androderm®
in Hypogonadal Men
Clinical Study Sponsor Allergan
Trial Phase Classification Phase [ADDRESS_827646] Indicator No
Planned Minimum Age of Subjects 18
Planned Maximum Age of Subjects 80
Sex of Participants Males
Stable Disease Minimum Duration N/A
Treatments Investigational Therapy or Treatment Androderm
Intervention T ype Drug
Dose per Administration 2 mg, 4 mg, or 6 mg
Dose Units
Dosing Frequency once daily
Route of Administration transdermal system
Trial design Study T ype Interventional
Intervention Model Single -group
Planned Number of Arms 1
Trial Is Randomized No
Trial Blinding Schema Open -label
Adaptive Design No
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827647] -T-01 -01 v3.010.7. Appendix 7: Contraceptive Guidance and Collection of Pregnancy 
Information
Contracept ionGuidance :
Male Participants
Nonvasectomize d male participants with female partners of childbearing potential are eligible to 
participat e if they  agree to ONE of the following during the protocol -defined timeframe in 
Section 5.1: 
Are abstinent from penile -vaginal intercourse as their usual and preferred lifestyle 
(abstinent on a long -term and persistent basis) and agree to remain abstinent
Agree to use a male condom  with spermicide  plus partner use of a contraceptive method 
with a failure rate of <  1% per y ear as described in Table10-[ADDRESS_827648] agree to 
remain abstinent from penile -vaginal intercourse or use a male condom during each epi[INVESTIGATOR_621750] d uring the protocol -defined time frame.
Table 10-2 Highly Effective and Acceptable Contraceptive Methods
Highly Effective Contraceptive Methods That Are User Dependenta
Failure rate of < 1% per year when used consistently and correctly
Com bined (estrogen -and progestogen -containing) hormonal contraception associated with inhibition of 
ovulationb
Oral 
Intravaginal 
Transdermal 
Progestogen -only hormonal contraception associated with inhibition of ovulation
Oral 
Injectable 
Highly Effective Methods That Are User Independenta
Implantable progestogen -only hormonal contraception associated w ith inhibition of ovulationb
IUD
IUS
Etonogestrel implant (ie, Nexplanon®)
Bilateral tubal occlusion (eg,Essure®, bilateral tubal ligation )
Intrauterine copper contraceptive (ie, ParaGard®)
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827649] -T-01 -01 v3.0Sexual Abstinence 
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study intervention. The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of 
the participant.
Acceptable Methods
Acceptable birth control methods that result in a failure of more than 1% per year include:
Progestogen -only oral hormonal contraception, where inhibition of ovulation is not the primary mode of 
action
Male or female co ndom  with or without spermicide
Cap, diaphragm, or sponge with spermicide
Nonhormonal intrauterine device
A combination of male condom with either cap, diaphragm, or sponge with spermicide (double -barrier methods) 
are also considered acceptable, but not highly effective, birth control methods.
aTypi[INVESTIGATOR_35818]. Use should be consistent 
with local regulations regarding the use of contraceptive methods for participants participating in clinical studies. 
bHormonal contraception m ay be susceptible to interaction with the study intervention, which may reduce the 
efficacy of the contraceptive method. In this case, 2highly effective methods of contraception should be u sed 
during the study intervention period and for at least [ADDRESS_827650] dose of study intervention .
Collection of Pregnancy Information:
Male Participants with Partners Who Become Pregnant 
The investigator will attempt to collect pregnancy  information on any  male participant’ s 
female p artner who becomes pregnant while the male participant is in this study . This 
applies only  to male participants who receive study intervention.
After obtaining the necessary  signed informed consent from the pregnant female partner 
directly , the investigator will record pregn ancy  information on the appropriate form and 
submit it to the sponsor within 24 hours of learning of the partner ’s pregnancy . The female 
partner will also be followed to determine the outcome of the pregnancy . Information on 
the status of the mother and ch ild will be forwarded to the  sponsor . Generally , the 
follow -up will be no longer than 6 to 8 weeks following the estimated delivery date. Any 
termination of the pregnancy  will be reported regardless of fetal status (presence or 
absence of anomalies) or ind ication for the procedu re. 
CONFIDENTIAL Protocol 3146 -402-016
Androderm®(testosterone transdermal sy stem)
[ADDRESS_827651] -T-01 -01 v3.011. References
Androderm®(testosterone transdermal sy stem) [package insert]. Madison, New Jersey : Allergan, 
Inc; 2018.
Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therap y in Men with Hypogonadism: 
An Endocrine Societ y Clinical Practice Guideline. J Clin Endocrinol Metab. 
2018;103:1715 -1744.
Dupont AG, van der Niepen P, Six RO. Placebo Does Not Lower Ambulatory  Blood Pressure. 
Br J Clin Pharmaco l. 1987;24:[ADDRESS_827652] on Ambulatory Blood Pressure. Am 
J Hypertens. 1995;8:[ADDRESS_827653] of Placebo on 24 -Hour Non -Invasive Ambulatory 
Blood P ressure. J Hy pertens. 1991;9:361 -364.
O’Brien E, Parati G, Stergiou G, et al. European Society of Hypertension Position Paper on 
Ambulatory  Blood Pressure Monitoring. J Hy pertens. 2013;31:1731 -1768.
Parati G, Stergiou G, O’Brien E, et al. European Society  of Hy pertension practice guidelines for 
ambulatory  blood pressure monitoring. J Hy pertens. 2014;32:1359 –1366.
Ullah MI , Riche DM, Koch CA. Transdermal testosterone replace ment therapy  in men. Drug 
Des Devel Ther. 2014;8:101 -112.